Mina Sooch is the president and CEO at Gemphire Therapeutics, a clinical-stage biotech company. Before that, she led ProNAI Therapeutics, where she raised the largest round of venture capital in the history of Michigan startups. Mina has also served as Managing Partner at Triathlon Medical Ventures Fund II.
Mina brings with her over fifteen years of pharmaceutical and healthcare experiences as an entrepreneur, strategy & finance advisor, and venture capitalist. Mina co-founded Apjohn Ventures Fund in 2003 in Kalamazoo, Michigan, where as Managing Partner she had been active in sourcing, screening, due diligence, closing, and company building at the nine fund investments. Mina has served on all the portfolio company Boards, including Asterand, ProNAi, Svelte, ZyStor, and CytoPherx. She also co-founded Apjohn Group a business accelerator in 2001 and launched several biotech start-ups. Mina currently chairs the board of the Michigan Venture Capital Association, which she has served on for six years, and has been a long time board member of the Midwest Healthcare Investment Network.
Prior to 2001, Mina spent eight years as a global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with her client base consisting of mid-cap and large-cap healthcare companies and multi-billion dollar private equity companies. With a focus on M&A, she has worked on over 30 deals
including $7B Pharmacia & Upjohn merger in 1995 and $1B merger of PharMerica in 1997. Mina was also a founding leader of Monitor's Corporate Finance practice in 1998. Mina began her career spending several years in research and product development at Ford Motor Company, Dow Chemical Company, and Proctor and Gamble.
Mina received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.